Puma Biotechnology, Inc. PBYI
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Puma Biotechnology, Inc. (PBYI) is a healthcare company listed in the US with a market value of about $402M. In the twelve months to September 30, 2026 it had revenue of $232M and net income of $24M, a net margin of 10.3%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is financial health (5/5); the weakest is shareholder returns (1/5).
Key numbers: a P/E of 16.9, a price to free cash flow of 8.7, 5-year revenue growth of 0% a year, a 5-year average ROIC of 14%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 51% below the current price.
About Puma Biotechnology
Puma Biotechnology is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $28M in 2017 to $228M in 2025, growth of about 30.2% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 13% over three years (dilution for shareholders). It spends 27% of revenue on research and development.
Score: 2.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $232M | $228M | $230M | $236M | $228M | $253M | $225M | $272M | $251M | $28M | — |
| Net income | $24M | $31M | $30M | $22M | $2000 | -$29M | -$60M | -$76M | -$114M | -$292M | -$276M |
| Free cash flow | $46M | $42M | $39M | $27M | -$16M | $21M | $727000 | $22M | -$25M | -$173M | -$146M |
| EPS (diluted) | $0.46 | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 | $-1.52 | $-1.95 | $-2.99 | $-7.85 | $-8.29 |
| Net margin | 10.3% | 13.6% | 13.1% | 9.2% | 0.0% | -11.5% | -26.7% | -27.8% | -45.2% | -1054.6% | — |
| ROIC | — | 20.4% | 14.6% | 18.6% | 13.4% | 0.9% | -20.9% | -22.4% | -40.2% | -226.9% | -104.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Puma Biotechnology’s P/E ratio?
About 16.9, based on the last twelve months of diluted earnings per share.
Is Puma Biotechnology stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 51% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Puma Biotechnology pay a dividend?
Not currently.
Is Puma Biotechnology a good stock to buy?
We do not give buy or sell advice. Puma Biotechnology scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.